Every piece of our research, in one place
209 published articles — supplier reviews, compound buyer guides, and head-to-head comparisons, all grouped by topic. Everything here is built on independent, blinded HPLC testing: 38 samples from 8 US suppliers, scored by named editor Mootez Chachia, with zero sponsorships.
See the full dataset in our 2026 purity report and exactly how we test in our published methodology.
Showing all 209 articles.
Supplier Review
16 articlesBlinded HPLC results and full scorecards for the US research peptide suppliers we have tested.
Limitless Life Nootropics Review (2026): HPLC-Tested
An independent 2026 review of Limitless Life Nootropics — blinded HPLC results, COA practices, shipping, pricing, and where this premium-documentation reseller fits. Scored 8.2/10.
Swiss Chems Review (2026): HPLC-Tested Purity, COAs & Who It's For
An independent 2026 review of Swiss Chems — blinded HPLC results, COA practices, shipping, pricing, and exactly where this mid-tier budget vendor fits. Scored 7.0/10.
Core Peptides Review (2026): HPLC + Mass Spec Analysis
We HPLC-tested 5 Core Peptides compounds across two independent labs. Results, scoring, and how they compare to ROEHN Research.
Instant Peptides Review (2026): Independent Evaluation
Independent 2026 evaluation of Instant Peptides (instantpeptides.com). Pricing, shipping, product line, and how they compare to top-ranked US research peptide suppliers.
Licensed Peptides Review 2026: 7.1/10 — Legit but Mid-Tier
Is Licensed Peptides legit? We scored them 7.1/10 in our 2026 evaluation. What 'licensed' really means, the COA gaps, and the full verdict.
Orbitrex Peptide Review (2026): Independent Evaluation
Independent 2026 evaluation of Orbitrex Peptide (orbitrexpeptide.is). Pricing, jurisdiction, product line, and how they compare to US-based research peptide suppliers.
Rebel Peptides Review (2026): Independent Evaluation
Independent 2026 evaluation of Rebel Peptides. Their bioregulator focus, pricing, product line, and how they compare to top-ranked US research peptide suppliers.
Pure Health Peptides Review (2026): Independent Evaluation
Independent 2026 evaluation of Pure Health Peptides (purehealthpeptides.com). Pricing, product line, testing practices, and ranking comparison.
ROEHN Research Review (2026): Is It the Best Peptide Supplier?
Deep-dive review of ROEHN Research. HPLC purity results across 5 compounds, shipping evaluation, COA quality, and the SERAPH protocol engine. Scored 9.6/10 in our 2026 annual report.
Prime Prometics Review (2026): Independent Evaluation
Independent 2026 evaluation of Prime Prometics. Pricing, product line, testing practices, and how they compare to our top-ranked US research peptide suppliers.
Based Supplies Review (2026): Independent Evaluation
Independent 2026 evaluation of Based Supplies as a research peptide supplier. Product line, pricing, testing claims, and ranking comparison.
Alpha Omega Peptide Review (2026): Independent Evaluation
Independent 2026 evaluation of Alpha Omega Peptide. Product line, pricing, testing practices, and how they compare to our top-ranked research peptide suppliers.
Northline Research Review (2026): Independent Evaluation
Independent 2026 evaluation of Northline Research. Pricing, product line, testing practices, and how they compare to our top-ranked US research peptide suppliers.
True Wellness Pro Review (2026): Independent Evaluation
Independent 2026 evaluation of True Wellness Pro. Pricing, product line, testing claims, and how they compare to our top-ranked US research peptide suppliers.
Power Peptides Review (2026): A Closer Look at the US Supplier
Independent 2026 evaluation of Power Peptides US (powerpeptides.com). Pricing, product line, testing practices, and how they stack up against top-ranked suppliers.
Certified-Pep Review (2026): Is It a Legit Research Peptide Supplier?
Independent 2026 evaluation of Certified-Pep / certified-global.com. Pricing, product line, ISO claims, and how they compare to our top-ranked US suppliers.
Buyer's Guide
21 articlesHow to source a specific compound in 2026 — what to verify, what it should cost, and where it tested well.
How Research-Peptide Pricing Actually Works: What You're Really Paying For
A breakdown of research-peptide pricing — what drives cost, why the same compound varies so widely between vendors, and why the cheapest option is usually a signal rather than a deal. Research-use framing throughout.
Reconstitution Solvents & Peptide Solubility: Bacteriostatic vs Sterile Water and When Neither Is Enough
Most research peptides dissolve cleanly in bacteriostatic water — but solubility is a chemistry problem, and a few compounds need a different solvent. Here is how solvent choice, pH, and peptide sequence interact, and why the wrong solvent leaves powder in the vial.
Underdosing Explained: Why a 5mg Vial Often Isn't 5mg of Peptide
Label-claim shortfalls are the quietest failure in research peptides — the vial passes a purity test but contains less peptide than printed. Here's where the milligrams actually go, and how to catch it.
Multi-Dose Vial Handling: Contamination Control for Reconstituted Research Peptides
A reconstituted research peptide vial is punctured dozens of times across a 30-day window. Each puncture is a contamination opportunity. Here is the septum-hygiene, coring, and draw discipline that keeps a multi-dose vial clean for its full life.
How to Vet a Brand-New Peptide Vendor (When There's No Track Record Yet)
A practical due-diligence framework for evaluating a research-peptide vendor with zero operating history — what to verify, what to ignore, and how to run a low-risk first order. Research-use framing throughout.
How to Read a Research-Peptide Product Label (Field Guide, 2026)
The vial label is the most overlooked verification tool in research peptides. Here's how to decode every field — net mass vs salt mass, lot codes, the RUO line — and the discrepancies that signal a problem.
Receiving a Cold-Chain Peptide Shipment: The Last-Mile Handling Checklist
Cold-chain ends at your door, not the carrier's. Here is how to inspect, triage, and stabilize a temperature-sensitive research peptide shipment the moment it arrives — and how to read the gel packs.
COA Fraud in Research Peptides: The Forgery Red Flags Most Buyers Miss
A Certificate of Analysis is easy to fake and hard to verify. Here are the forensic red flags that separate a fabricated COA from a real one — and how to confirm authenticity at the source.
Choosing Insulin Syringes for Research Peptide Reconstitution
Gauge, length, barrel volume, and unit scale all change how cleanly a reconstituted research peptide reads on the syringe. Here is how to choose insulin syringes for handling work — and why the wrong barrel ruins your measurement resolution.
Tirzepatide Buyer's Guide 2026: Sources, Purity, and What to Watch
We HPLC-tested 6 tirzepatide vendors in 2026. Purity ranged from 92.4% to 98.9%. Here's the full vendor evaluation, the 4 red flags, and a reconstitution guide.
How to Read a Peptide COA: 8 Checks Before You Trust It
Most peptide COAs are decorative, not informative. Here's how to read a peptide COA the right way — the 8 elements a real Certificate of Analysis must contain, and which third-party labs the research community actually trusts.
Are Research Peptides Legal in 2026? The FDA Update Explained
Yes, research peptides are legal to buy and sell for laboratory research in the US — with important caveats. Here's what the 2023 FDA reclassification actually changed, and what it didn't.
Why Most Peptide COAs Are Worthless (And the 3 Suppliers That Aren't)
We reviewed 8 suppliers' Certificates of Analysis in 2026. Five had problems that made them effectively useless for buyer verification. Here's what to look for.
Janoshik vs MZ Biolabs: Which Third-Party Peptide Lab Should You Use?
The two third-party labs the research community trusts most. Compared on HPLC methodology, pricing, turnaround time, and what each lab tests for.
15 Peptide Vendor Red Flags: How to Spot a Scam Supplier (2026)
Counterfeit peptides have tested as low as 7.7% purity vs 99% claimed. Here are 15 red flags that separate legitimate research compound suppliers from scams.
Peptide Reconstitution Guide: How to Mix BPC-157, Semaglutide, and Other Research Peptides
The universal reconstitution protocol for research peptides. Bacteriostatic water math, step-by-step procedure, compound-specific notes, and the 5 mistakes that ruin vials.
BPC-157 Buyer's Guide: How to Choose a Supplier in 2026
Everything researchers need to know about sourcing BPC-157 in 2026. How to verify purity, what COAs actually mean, shipping pitfalls to avoid, and a head-to-head ranking of the 8 most-ordered US suppliers.
GHK-Cu (Copper Peptide) Buyer's Guide (2026): Research-Grade Sourcing
GHK-Cu is a copper-binding tripeptide studied in wound healing and skin research models. Independent guide to sourcing, what makes the copper complex unique, and 2026 supplier comparison.
CJC-1295/Ipamorelin Buyer's Guide (2026): DAC vs No-DAC, Sourcing, and Quality
The CJC-1295/Ipamorelin blend is the most-studied growth hormone secretagogue combination. Independent guide to sourcing, the DAC vs no-DAC distinction, and 2026 supplier HPLC purity results.
TB-500 Buyer's Guide (2026): How to Source Thymosin Beta-4 Research Peptide
Independent guide to sourcing TB-500 for tissue repair research. HPLC purity comparison, supplier evaluation, and what separates a real Thymosin Beta-4 fragment from a fake one.
NAD+ Buyer's Guide (2026): How to Source Research-Grade NAD+
Independent guide to sourcing NAD+ for laboratory research. HPLC purity verification, supplier comparison, storage requirements, and what to watch for.
Comparison
20 articlesHead-to-head breakdowns when readers are choosing between two suppliers or two compounds.
Tirzepatide vs Retatrutide (2026): Dual vs Triple Agonist Research Comparison
A research-framed comparison of tirzepatide and retatrutide — the receptor systems each engages, why a triple agonist differs from a dual one, and how the maturity of their evidence bases diverges. Mechanism over marketing.
Semaglutide vs Retatrutide: A Research Comparison (2026)
How the single GLP-1 agonist semaglutide compares to the triple-agonist retatrutide as research compounds — receptor pharmacology, molecular complexity, sourcing risk, and verification, framed strictly for laboratory use.
NAD+ vs Longevity Peptides (2026): Different Molecules, Different Aging Pathways
A research-framed comparison of NAD+ and the peptides it's grouped with — epithalon, mitochondrial peptides, and others. Why NAD+ isn't even a peptide, what pathway each targets, and how to read the longevity-research category honestly.
Melanotan II vs PT-141: A Research Comparison (2026)
Parent and metabolite, side by side. How the non-selective melanocortin agonist melanotan II compares with its centrally-acting descendant PT-141 — receptor selectivity, the regulatory split, and why their structural closeness makes mass-spec identity confirmation essential. Framed for laboratory research.
Ipamorelin vs MK-677: A Research Comparison (2026)
Two growth-hormone secretagogues, two completely different molecules. How injectable peptide ipamorelin compares to the orally-active small molecule MK-677 (ibutamoren) — receptor pharmacology, pharmacokinetics, selectivity, and sourcing — framed for laboratory research.
GLP-1 vs Dual-Agonist Peptides (2026): A Research Comparison
Single-receptor GLP-1 agonists vs dual and triple incretin co-agonists. A research-framed comparison of receptor biology, why adding GIP and glucagon receptors changes the question, evidence maturity, and sourcing implications.
GHK-Cu vs Other Copper-Delivery Compounds: A Research Comparison (2026)
How the copper tripeptide GHK-Cu compares with other ways of delivering copper in research — free GHK, the related peptide AHK-Cu, and inorganic copper salts. Coordination chemistry, the role of the peptide carrier, and why the delivery vehicle matters, framed for laboratory use.
CJC-1295 vs Tesamorelin (2026): Two GHRH Analogs, Two Research Stories
A research-framed comparison of CJC-1295 and tesamorelin — both GHRH-analog peptides, but one is a research-built long-acting compound and the other a clinically developed agent with a defined trial record. Mechanism and evidence.
CJC-1295 vs Sermorelin (2026): GHRH Analog Research Comparison
Two GHRH-analog research peptides separated mostly by half-life. A research-framed comparison of structure, the DAC distinction, pulsatility, evidence, and what the half-life gap means for protocol design and sourcing.
BPC-157 vs TB-500 for Recovery Research (2026): Mechanism Comparison
Two tissue-repair peptides constantly named in the same breath — but they act on different mechanisms. A research-framed comparison of structure, studied pathways, evidence depth, and sourcing for BPC-157 and TB-500.
BPC-157 vs GHK-Cu (2026): Two Tissue-Repair Peptides, Two Very Different Mechanisms
A research-framed comparison of BPC-157 and GHK-Cu — why one is studied for systemic tissue and gut models and the other for skin, copper transport, and dermal remodeling. Mechanism, evidence, and what separates them.
Best Peptide Vendors on Reddit (2026): What the Threads Get Right & Wrong
Reddit is where most researchers go for peptide vendor recommendations — but the threads have real blind spots. Here's how to read them critically, and what blinded HPLC testing actually shows in 2026.
Semaglutide vs Tirzepatide (2026): Research Buyer's Comparison
How the two GLP-1 class compounds compare from a research-peptide-buyer perspective: supplier landscape, purity test results, pricing, and which to source first.
Best Peptide Lab Manufacturers 2026: Reviews & HPLC Results
Which peptide brands actually synthesise in-house versus resell? Our 2026 manufacturer reviews separate the labs from the relabellers — with HPLC data on what each ships.
Best Peptide Suppliers 2026: Independent Lab Test Reviews
Independent 2026 reviews of 8 US peptide vendors: 38 blinded HPLC purity tests reveal which suppliers match label claims — and which fail by 7+ points.
Best Peptide Sciences Alternative in 2026 (After the Shutdown)
Peptide Sciences voluntarily shut down in March 2026. Here's where their customers should go next — based on our blinded HPLC testing of 8 US suppliers.
ROEHN vs Prime Lab vs Peptide Sciences: 3-Way Comparison (2026)
The three suppliers most often searched together — compared on tested HPLC purity, documentation, shipping, catalog breadth, and current operating status.
Best BPC-157 Supplier (2026): HPLC Purity Test Results from 8 Suppliers
Which BPC-157 supplier actually delivers the purity they claim? We ordered from 8, blinded the samples, and ran them through an independent HPLC lab. Here's what we found.
Prime Lab Peptides vs ROEHN Research: Side-by-Side Comparison (2026)
The two top-ranked suppliers in our 2026 evaluation, compared compound by compound. Both passed our purity tests — but they're different products for different researchers.
8 Semaglutide Suppliers Tested by HPLC: 3 Failed (2026)
We HPLC-tested Semaglutide from 8 suppliers in 2026. Three missed their label claims — one by 7.7 points. Full purity rankings, 98.7% to 91.3%, inside.
Compound Guide
15 articlesResearch-literature reference for individual peptides: properties, handling, and storage.
Tesamorelin Research Profile (2026): The Stabilized GHRH Analog
A long-form research profile of tesamorelin — the stabilized growth-hormone-releasing hormone analog and the only FDA-approved compound of its class. Discovery, structure, mechanism, and current research status.
TB-500 vs Thymosin Beta-4: Fragment vs Full-Length in the Research Literature
TB-500 and Thymosin Beta-4 are routinely conflated, but one is a synthetic fragment and the other the full-length parent protein. A research-framed look at the structural distinction, the shared active region, and why it matters for sourcing.
PT-141 Research Profile (2026): The Melanocortin Agonist That Acts on the Brain
A long-form research profile of PT-141 (bremelanotide) — the centrally-acting melanocortin-receptor agonist with an FDA-approved pharmaceutical identity. Discovery from a tanning peptide, structure, mechanism, and status.
Melanotan II Research Profile (2026): The Non-Selective Melanocortin Analog
A long-form research profile of melanotan II — the synthetic alpha-MSH analog studied in pigmentation research and the parent compound of PT-141. Discovery, cyclic structure, mechanism, and an honest read on its status.
Ipamorelin Selectivity: What 'Selective' Actually Means in the Research
Ipamorelin's reputation rests on one word — selectivity. A research-framed deep dive into the pharmacology behind that claim: which receptor it engages, which off-target pathways it spares, and how that profile compares to earlier GHRPs.
Ipamorelin Research Profile (2026): The Selective Ghrelin-Receptor Agonist
A long-form research profile of ipamorelin — the selective growth-hormone secretagogue prized in research for its clean receptor profile. Discovery, the pentapeptide structure, mechanism, and current status.
CJC-1295 With DAC vs Without DAC: The Half-Life Split That Defines Two Compounds
'CJC-1295' is not one molecule. The DAC and no-DAC versions are kinetically distinct research compounds separated by albumin binding. A research-framed look at the mechanism of the split, what it means for pulsatility, and why it's a verification step.
BPC-157 Oral vs Injectable: What the Research Literature Actually Compares
BPC-157 appears in the research literature by both oral and parenteral routes. A research-framed look at what the route distinction means for stability, distribution, and how published studies are designed — not a usage guide.
BPC-157 + TB-500 'Wolverine Stack': What the Research Says
The most-discussed peptide stack on Reddit. What research has examined, why the two compounds work on different mechanisms, and how to source both at research-grade purity.
Tirzepatide vs Semaglutide: Research Compound Comparison (2026)
Two GLP-1 research compounds with different mechanisms. We compare them on structure, available research, supplier availability, and tested purity from US suppliers.
What Is BPC-157? A Research Guide to the Body Protection Compound
BPC-157 is one of the most-studied research peptides in tissue repair models. Here's what the literature says about it — and what to look for when sourcing for research.
Retatrutide Research Guide (2026): Triple-Agonist Metabolic Research
Retatrutide is a synthetic triple receptor agonist (GIP/GLP-1/glucagon) under preclinical and clinical investigation by Eli Lilly. Independent research guide to sourcing and supplier quality.
AOD-9604 Research Guide (2026): The Fat Metabolism Fragment
AOD-9604 is a synthetic peptide fragment of human growth hormone (residues 176-191) studied in lipid metabolism research models. Sourcing guide and 2026 supplier evaluation context.
Semax Research Guide (2026): Nootropic Peptide Sourcing & Quality
Semax is a synthetic heptapeptide developed in Russian research labs as a nootropic and neuroprotective compound. Independent guide to sourcing, mechanism, and supplier quality.
Selank Research Guide (2026): What It Is, Where to Source It
Selank is a synthetic heptapeptide originally developed in Russian research labs for anxiolytic and cognitive research. Guide to its mechanism, sourcing, and supplier quality.
Where to Buy
1 articleCommercial-intent sourcing guides tied to our vendor evaluations.
Field Guide
2 articlesPractical bench references for handling, reconstituting, and storing research peptides.
Peptide Storage and Shelf-Life Guide (2026)
How long peptides actually last lyophilized vs reconstituted, the freeze-thaw rule, compound-specific shelf lives, and the signs your peptide has degraded — even if it still looks fine.
GHK-Cu Reconstitution and Storage Guide (2026)
How to reconstitute GHK-Cu correctly, why the color matters, storage protocols, and the copper-coordination quirks that make this peptide different from BPC-157 or TB-500.
Industry Investigation
1 articleDeeper reporting on how the research peptide market actually operates.
Investigation
1 articleDeeper reporting on how the research peptide market actually operates.
Industry Analysis
3 articlesMarket-level analysis of suppliers, pricing, and the 2025–2026 shakeout.
Why Research-Peptide Vendors Collapse: The Structural Reasons Brands Don't Last
Vendor shutdowns aren't random bad luck. A look at the structural reasons research-peptide brands collapse — thin margins, regulatory exposure, payment fragility, and trust debt — and the early signals that precede a closure. Research-use framing throughout.
The 2026 Research-Peptide Vendor Landscape: How the Market Is Actually Structured
A map of the 2026 research-peptide vendor market — the tiers, the business models behind them, and why the field looks the way it does after a year of consolidation. Research-use framing throughout.
Peptide Vendor Migration Map (2025-2026): Where 4 Collapses Sent the Market
Peptide Sciences. Amino Asylum. Paradigm Peptides. Science.bio. Four major US research peptide vendors shut down in 18 months. We tracked where their customers migrated and what the survivors have in common.
Educational
1 articleFoundational explainers for readers new to research peptide testing.
Glossary
4 articlesPlain-language definitions of the testing and documentation terms used across the site.
What Is a Certificate of Analysis (COA)?
A Certificate of Analysis is the document that tells you what is actually in a peptide vial. Here is what a real COA must contain and how to tell a batch-specific certificate from a marketing flyer.
What Is Lyophilization? (Why Research Peptides Are Freeze-Dried)
Lyophilization is the freeze-drying process that turns a peptide solution into the white powder you receive in a vial. Here is how it works and what a good lyophilization job looks like.
What Is Bacteriostatic Water? (A Guide for Research Peptide Use)
Bacteriostatic water is the standard solvent for reconstituting research peptides. Here is what makes it different from sterile water, why the preservative matters, and how to store it.
What Is HPLC? (Plain-English Guide for Peptide Buyers)
HPLC is the analytical method behind every legitimate peptide purity claim. Here is what the acronym means, how the test works, and how to read the chromatogram on a supplier's COA.
Industry
1 articleIndependent reporting and reference filed under Industry.
Research Guide
123 articlesIndependent reporting and reference filed under Research Guide.
Why Peptides Degrade: The Chemistry of Hydrolysis, Oxidation, and Aggregation (2026)
A bond-level look at why research peptides break down — peptide-bond hydrolysis, deamidation, methionine and cysteine oxidation, and physical aggregation — and which chemistry each storage control is actually targeting.
Why Most Peptides Are Injected, Not Oral: The Bioavailability Problem (2026)
Swallow a peptide and almost none reaches circulation. A research-framed deep dive into the two barriers that wreck oral peptide bioavailability — enzymatic digestion and the gut wall — and the formulation tricks researchers use to get around them.
Why Cheap Peptides Fail Purity Testing: The Economics Behind a Low Number (2026)
An unusually cheap peptide is not a bargain hiding in plain sight — it is usually the visible end of a chain of skipped steps that show up later as a low purity result. Here is the chemistry and the cost structure that explain why price and purity are linked, without assuming every cheap vial is bad.
What Reconstitution Actually Does at the Chemistry Level (2026): Solvation, Hydration & Refolding
Reconstitution looks like 'add water, swirl, done' — but at the molecular level it's a solvation and rehydration event that re-creates the peptide's solution state. A research-framed explainer of what really happens when lyophilized powder meets solvent, and why technique is chemistry.
What '98% Purity' Actually Means on a Peptide COA (2026)
98% purity sounds precise, but the number hides a stack of assumptions: what basis it was measured on, what the other 2% is, and why 98 is closer to a normal result than a red flag. Here is how to read the headline purity figure for what it actually says.
VEGF and Angiogenesis Signaling in Peptide Research (2026)
How VEGF drives new blood-vessel formation — the ligand family, VEGFR receptor tyrosine kinases, and the angiogenic cascade — and why angiogenesis surfaces as a proposed, still-preclinical pathway in recovery-peptide research. A research-framed signaling explainer with honest hedging.
The US Research-Chemical Legal Framework in Depth (2026): The Anatomy of the 'Research Use Only' Lane
A structural deep-dive into how the US actually treats research-use compounds — the FDCA, the RUO labeling doctrine, why DEA scheduling doesn't apply, the FTC's separate role, and the state layer. The most detailed map in the series. Not legal advice.
What Makes a Certificate of Analysis Trustworthy? The Trust Signals That Separate Evidence From Decoration (2026)
A purity number on a PDF is easy to print. What makes a Certificate of Analysis actually trustworthy is the chain of verifiable signals behind that number — traceability, raw data, an attributable analyst, and consistency you can cross-check. Here is how to weigh them.
Thymosin Alpha-1 Research Overview (2026): The Immune-Modulating Peptide
A research-framed overview of thymosin alpha-1 — the thymus-derived immunomodulatory peptide. Origin, mechanism, its distinction from thymosin beta-4, and an honest read on the evidence.
Third-Party Peptide Lab Testing Explained: How Independent Verification Actually Works (2026)
Sending a vial to an outside lab is the closest thing the research peptide market has to an audit. Here is how third-party testing works end to end — what gets measured, identity vs purity vs sterility, chain of custody, and how to read the result you get back.
Tesamorelin vs MK-677: Two Very Different Ways to Raise GH (2026)
Tesamorelin is an injectable GHRH-analog peptide; MK-677 is an orally active non-peptide ghrelin-receptor agonist. A research-framed comparison of mechanism, format, and why they aren't the same kind of tool at all.
Tesamorelin GHRH Mechanism (2026): GHRH-R, cAMP & the Pituitary Pulse
How tesamorelin works at the receptor level — binding the pituitary GHRH receptor, Gs/cAMP signaling in somatotrophs, the trans-3-hexenoyl stabilization against DPP-4, and why an upstream secretagogue differs from recombinant GH. A research-use mechanism guide.
Tendon & Ligament Repair: What the Peptide Research Actually Shows (2026)
A research-framed look at the peptides studied in tendon and ligament healing models — BPC-157, TB-500 and growth-factor signaling — what the mechanisms suggest, and where the evidence is still preclinical.
Sterility vs Purity vs Potency: Three Different Tests, Three Different Questions (2026)
Sterility, purity, and potency get used almost interchangeably in peptide marketing, but they are three separate measurements answering three unrelated questions. A vial can pass one and fail another. Here is what each test does, what it cannot tell you, and why no single number covers all three.
Sermorelin: A Research Overview of the GHRH Analog (2026)
A research-framed overview of sermorelin — the GHRH(1–29) fragment, how it differs mechanistically from the GHRP secretagogues, its short half-life, its regulatory history, and what the literature establishes versus what marketing implies.
Semax Nootropic Research: BDNF, Neuroplasticity & the ACTH Connection (2026)
A research-framed deep dive into how Semax is studied as a nootropic — the ACTH(4-10) ancestry, BDNF and NGF modulation, neuroplasticity findings, and what is established versus speculative. Research use only.
Selank vs Semax: How the Two Russian Neuropeptides Compare in Research (2026)
A research-framed comparison of Selank and Semax — two synthetic neuropeptides from the same Russian research tradition, with different parent molecules, different proposed mechanisms, and different study emphases. Mechanism, not advice.
Selank Anxiolytic Research: GABA, Serotonin & the Anti-Stress Mechanism (2026)
A research-framed look at why Selank is studied as an anxiolytic — the proposed GABAergic and serotonergic modulation, enkephalin stabilization, and what separates established findings from speculation. Research use only.
Retatrutide Triple-Agonist Mechanism (2026): GLP-1, GIP & Glucagon Signaling
A receptor-by-receptor breakdown of how retatrutide engages three targets at once — GLP-1, GIP, and the glucagon receptor — what each signaling arm adds, and why the glucagon arm is the mechanistic novelty. Research-use framing throughout.
Retatrutide Research Timeline: How Incretin Science Reached the Triple Agonist (2026)
A research-framed timeline of how incretin pharmacology progressed from single to dual to triple receptor agonists, and where Retatrutide (LY3437943) sits in that publicly disclosed development arc. Context, not outcomes.
Research Protocol Design for Peptides: Turning a Compound Into a Real Experiment (2026)
How a rigorous peptide research protocol is built — defining endpoints, controls, blinding, and dosing variables — so that results mean something. A study-design framework, not a dosing regimen.
Research Peptide Regulation in the UK and Australia (2026): Two Stricter Frameworks Compared
The UK and Australia both regulate research-use compounds more tightly than the US in important respects. An informational overview of the MHRA, the TGA, the research-chemical framing in each, and why import scrutiny is the recurring theme. Not legal advice.
Research Peptide Regulation in the EU (2026): How the Bloc Treats Research-Use Compounds
An informational map of how research peptides are positioned in the European Union — the EMA's role, the research-chemical framing under EU law, why member states differ, and what it means for buyers. Not legal advice.
What 'Research Chemical' Classification Actually Means for Peptides in 2026
The phrase 'research chemical' is a real classification, not marketing fluff — but it is widely misunderstood. This is an informational breakdown of what the category includes, what it excludes, and how peptides fit. Not legal advice.
Reproducibility and Replication in Peptide Research: Why One Study Is Never Enough (2026)
A research-framed guide to reproducibility and replication in peptide studies — the difference between the two, why single findings so often fail to hold, and how to weight evidence by replication.
How Reference Standards Work in HPLC Quantification (2026)
Area-percent purity compares peaks to each other. To measure how much peptide is actually present, a lab needs a reference standard — a known-quantity sample that calibrates the instrument. Here is what a reference standard is, how a calibration curve turns a peak into a number, and why standard-calibrated content is a different claim than area-percent purity.
Reconstitution Concentration Math Explained: The Numbers Behind Every Research Vial (2026)
The arithmetic that turns a lyophilized vial into a known concentration — mass over volume, reading an insulin syringe in units, and the off-by-a-factor errors that silently corrupt research data. A math primer, not dosing advice.
Reconstituted Peptide Shelf Life: The Six Factors That Decide How Long the Window Lasts (2026)
Once a peptide is mixed with water the stability clock starts — but the length of that window is not fixed. Temperature, the diluent and its preservative, light, concentration, pH, and container all push it. A research-framed breakdown of what controls reconstituted shelf life.
Receptor Desensitization & Tachyphylaxis in Peptides, Explained (2026)
Why a peptide's effect can fade with continuous exposure — a research-framed explainer of receptor desensitization, downregulation, and tachyphylaxis, and why pulsatile dosing and washout windows appear in study protocols.
Receptor Binding Affinity Explained for Peptides (2026): What Kd, On-Rate and Off-Rate Actually Mean
Affinity is the single number researchers reach for to describe how tightly a peptide grips its receptor — but it hides as much as it reveals. A research-framed explainer of Kd, on-rate, off-rate, potency vs affinity, and why selectivity matters more than a small number.
Purity vs Potency in Peptide QC: Why a 99% Vial Can Still Be Underfilled (2026)
Purity is the ratio of target peptide to impurities. Potency — content — is how much peptide is actually in the vial. They are different measurements, and a high-purity vial can still hold less material than its label claims. Here is how to tell them apart.
PT-141 Melanocortin Mechanism (2026): How MC4R Signals in the Brain
A molecular-level look at how PT-141 (bremelanotide) works — agonism at the MC4 melanocortin receptor, Gs/cAMP coupling in hypothalamic neurons, and why a central mechanism is fundamentally different from peripheral vascular drugs. Research-use framing throughout.
Preclinical vs Clinical Evidence in Peptides: Why the Gap Matters (2026)
Most peptide claims rest on preclinical data — and the jump from a cell or animal result to a human one is where promising compounds quietly fail. A research-framed look at the translation gap.
Placebo and Vehicle Controls in Peptide Studies: What a Fair Comparison Actually Requires (2026)
A research-framed guide to control conditions in peptide studies — placebo vs vehicle, why the control must be indistinguishable, active comparators, and how a weak control silently inflates an effect.
Peptides vs Traditional Anabolics: A Research-Use Comparison (2026)
Growth-hormone secretagogue peptides and anabolic-androgenic steroids are different chemical classes acting through entirely different mechanisms. A research-framed comparison of structure, signaling, regulation, and verification.
Peptides vs SARMs: A Research-Use Comparison (2026)
Peptides and SARMs are frequently lumped together but differ at the level of chemistry, mechanism, and regulation. A research-framed comparison of what each class is, how they act, and why the distinction matters for sourcing and documentation.
Peptides in Sleep Research: What the Literature Actually Examines (2026)
A research-framed map of the peptides studied in sleep and circadian models — growth-axis secretagogues, the GH/slow-wave-sleep link, and anxiolytic compounds — organized by the mechanism each one engages. Mechanisms only, no human-outcome claims.
Peptides in Skin & Cosmetic Research: A 2026 Map of the Class
A research-framed overview of the peptides studied in skin, wound, and dermal models — copper-binding peptides, signal and carrier peptides, and pigmentation-pathway compounds — organized by the mechanism each one engages. Mechanisms only, no cosmetic-outcome claims.
Peptides in Joint & Cartilage Research: What the Literature Shows (2026)
A research-framed overview of the peptides studied in joint and cartilage models — cytoprotective and angiogenic compounds, actin-regulating fragments, and growth-axis signaling — with a focus on chondrocytes and the cartilage matrix. Mechanisms only, no human-outcome claims.
Peptides in Gut-Health Research: A 2026 Overview of the Class
A research-framed map of the peptides studied in gastrointestinal models — the gastric-derived cytoprotective peptide, anti-inflammatory fragments, and incretin agonists with gut-motility effects — organized by the mechanism each one engages. Mechanisms only, no human-outcome claims.
Peptide vs Protein vs Amino Acid: The Size & Structure Distinctions (2026)
Amino acid, peptide, protein — they sit on one continuum of size and structure. A research-framed explainer of where the lines fall, why molecular weight and bond count matter, and how the distinction shapes everything downstream.
Peptide Storage and Degradation: What Breaks Peptides Down and How Storage Slows It (2026)
A research-framed look at how peptides degrade — hydrolysis, oxidation, aggregation — and why lyophilized vs reconstituted state, temperature, light, and pH determine shelf life. The science behind cold-chain and refrigeration.
How Peptide Stability Is Actually Tested: Forced Degradation, Accelerated & Real-Time Studies (2026)
Knowing a peptide degrades is not the same as knowing how fast. This is a research-framed walkthrough of how stability is measured — forced degradation, accelerated studies, real-time studies, and the stability-indicating assays behind a shelf-life claim.
Peptide Stability in Solution (2026): What Actually Degrades a Reconstituted Peptide
A dry peptide is durable; the moment it's in solution the clock starts. A research-framed look at the specific chemistry that breaks down a reconstituted peptide — hydrolysis, deamidation, oxidation, aggregation, and adsorption — and which solution variables drive each.
Peptide Safety Monitoring in Research: What the Literature Actually Tracks (2026)
A research-framed overview of how peptide studies monitor for adverse signals — the biomarkers, observation windows, and documentation practices that define rigorous safety surveillance, described strictly as methodology rather than guidance for human use.
Keeping a Peptide Research Log: What to Record and Why It Matters (2026)
A reconstituted vial is only as trustworthy as the record behind it. What belongs in a peptide research log, why batch and reconstitution metadata are the load-bearing fields, and how a disciplined record turns inconsistent results into a traceable answer.
The Research Peptide Regulatory Landscape in 2026: Who Regulates What, and Why It Matters
Research peptides sit at the intersection of several regulatory bodies and frameworks — not one. This is an informational map of how that landscape is structured in 2026, which agency governs which question, and what it means for buyers. Not legal advice.
Peptide Legal Status by Region in 2026: A Research-Use Map of US, EU, UK, Canada & Australia
Research-peptide legality is not one global rule — it shifts at every border. This is an informational, region-by-region map of how the research-use framing is positioned across major markets in 2026. Not legal advice.
Peptide Impurity Profiles: What the Small Peaks Actually Tell You (2026)
The impurity peaks on a chromatogram are not just noise subtracted from a purity number — they are a record of how the peptide was made and how it has aged. Deletion sequences, truncations, oxidation products, and counter-ion adducts each leave a recognizable signature. This is a research-framed reading of what those signatures reveal about synthesis and storage.
International Peptide Import for Research Buyers: A Practical Customs Primer (2026)
If you source research-use compounds across a border, the import layer is where most friction lives. This is a practical, buyer-facing primer on documentation, declaration, country scrutiny, and why domestic sourcing sidesteps it all. Not legal advice.
Research Peptides and Customs: How Import Handling Works for Research-Use Compounds (2026)
Where research peptides cross a border, a separate set of rules and risks applies. This is an informational overview of how customs handling, labeling, and the research-use framing intersect at import — and why domestic sourcing changes the picture. Not legal advice.
Peptide Half-Life and Timing: A Pharmacokinetics Primer for Research (2026)
What half-life means, how it shapes administration timing in research protocols, and why modifications like acylation and PEGylation extend it — a research-framed pharmacokinetics primer, not dosing advice.
Peptide Frequency and Timing in Research: How Protocols Decide When to Administer (2026)
How published research reasons about administration frequency and timing — dosing intervals, pulsatile vs steady-state goals, and circadian considerations — framed as study-design description, not a usage schedule.
Peptide Cycling in Research Protocols: How and Why Studies Use Cycles (2026)
Why research protocols often structure peptide administration into on/off cycles — covering receptor desensitization, washout, and study-design logic, framed strictly as literature description rather than a usage regimen.
Peptide Customs and Import by Region (2026): How Destination Posture Differs Across Markets
Import scrutiny for research-use compounds varies enormously by destination. This is a region-by-region reference map — the US, EU, UK, Australia, Canada, and beyond — of how customs posture differs and why the destination country, not the document, governs the outcome. Not legal advice.
Peptide Contraindications and Interactions in Research (2026)
A research-framed look at how the literature reasons about contraindications and interactions for peptides — drawing on mechanism, overlapping pathways, and the regulated metabolic drugs — described as scientific reasoning, never as personal clinical guidance.
Peptide Aggregation Explained: What Causes Clumping and Why It Often Can't Be Reversed (2026)
Aggregation is the physical degradation pathway that clumps peptide molecules together — driven by concentration, interfaces, agitation, freeze-thaw, and pH. Here is what causes it, why it is frequently irreversible, and what it looks like in the vial.
Peptide Administration Routes in Research: Why Most Are Subcutaneous (2026)
A research-framed overview of the routes used to administer peptides in study protocols — subcutaneous, intramuscular, intranasal, oral — and the bioavailability reasons most research peptides are injected rather than swallowed.
NAD+ vs NMN vs NR: Comparing the Three Molecules in Precursor Research (2026)
A research-framed, head-to-head comparison of NAD+ itself versus its two leading precursors, NMN and NR — what each molecule is, how uptake and conversion differ, and why the 'which precursor' debate is narrower than the marketing suggests. Mechanism, not advice.
NAD+ Precursor Research: NMN, NR and the Pathways Behind the Hype (2026)
A research-framed explainer on NAD+ precursors — what NMN and NR are, how the salvage pathway works, and what the human evidence does and doesn't establish. Mechanism, not marketing.
Myostatin Inhibitors: A Research Overview of Follistatin and the Myostatin Pathway (2026)
A research-framed overview of the myostatin signaling pathway and the molecules studied to modulate it — including follistatin — with an honest account of where the science stands and why category-level claims are unsupported.
MK-677 (Ibutamoren) Research Overview (2026): Mechanism, Class & How to Read the Literature
A research-framed overview of MK-677 (ibutamoren) — why it is an orally active, non-peptide ghrelin-receptor agonist rather than a peptide, how it signals through GHS-R1a, and how to read its preclinical and clinical literature accurately.
Mitochondrial Peptides: MOTS-c and SS-31 in the Research Literature (2026)
An accurate, research-framed overview of mitochondrial-derived and mitochondria-targeted peptides — what MOTS-c and SS-31 are, where they act, and how the science distinguishes these two very different molecules.
Mitochondrial-Function Peptide Research: Energetics, Biogenesis and the Open Questions (2026)
A research-framed look at how peptides intersect with mitochondrial function — what the electron transport chain and biogenesis actually involve, and what the literature does and doesn't establish. Mechanism over marketing.
Metabolic Research Peptides: A 2026 Overview of the Class
A research-framed map of the metabolic peptide landscape — incretin agonists, the hGH lipolytic fragment, and growth-axis secretagogues — organized by the pathway each one engages. Mechanisms only, no human-outcome claims.
Melanotan II Mechanism (2026): Non-Selective Melanocortin Receptor Signaling
How melanotan II works across the melanocortin receptor family — MC1R-driven melanogenesis, MC4R central signaling, and why non-selectivity defines its pharmacology. A molecular mechanism guide written for research use only.
The Melanocortin Receptor Family Explained (2026): MC1R Through MC5R
A systematic guide to the five melanocortin receptors — MC1R through MC5R — their native ligands, tissue roles, and why receptor selectivity is the central pharmacological problem for melanocortin peptides studied in research. A research-framed receptor-family explainer.
BPC-157 Mechanism of Action: What Is and Isn't Established (2026)
A research-framed deep dive into the proposed mechanisms of BPC-157 — the nitric oxide pathway, VEGF/angiogenesis signaling, and the growth-hormone-receptor finding — separating what preclinical work supports from what remains speculative.
Mass Spectrometry for Peptide Identity: How Labs Confirm You Got the Right Molecule (2026)
HPLC tells you how pure a peptide is. Mass spectrometry tells you whether it is even the right peptide. Here is how mass spec confirms identity by molecular weight, why it is the assay buyers skip most, and how to read a mass-spec result on a COA.
Lyophilization Deep Dive: How the Freeze-Drying Cycle Actually Works for Peptides (2026)
Beyond 'freeze-drying': the three-stage lyophilization cycle, glass transition and cake collapse, the role of lyoprotectants and bulking agents, residual moisture, and why a clean cake is a quality signal for research peptides.
Long-Term Storage of Lyophilized Peptides: Keeping the Dry Vial Stable (2026)
The dry, freeze-dried vial is the most stable form a research peptide takes — but only if it is stored as though it still mattered. The factors that govern lyophilized shelf life, why the sealed cake outlasts any solution, and how to archive vials for months without touching the chemistry.
LL-37 Peptide Research Overview (2026): The Human Cathelicidin
A research-framed overview of LL-37, the only human cathelicidin antimicrobial peptide. Structure, its dual antimicrobial and immunomodulatory roles, and an honest read on where the preclinical evidence stands.
Lipolysis and Fat-Metabolism Peptides in Research (2026)
A pathway-level look at how research peptides are studied to intersect lipolysis — the cAMP/HSL cascade, direct fragments vs growth-axis routes vs incretin signaling, and why 'fat metabolism' covers several distinct mechanisms. Research-use framing only.
The Legal Status of Research Peptides in 2026: How the 'Research Use Only' Framing Works
An informational overview of how research peptides are positioned legally in 2026 — the 'for laboratory research use only' framing, why it matters, and the distinction between research chemicals and approved drugs. Not legal advice.
LC-MS for Peptide Identity Confirmation: How Two Instruments Work as One (2026)
LC-MS is not a single test but two analytical methods wired together — liquid chromatography to separate, mass spectrometry to identify. Here is how the hyphenated technique works, what each half contributes, and how to read an LC-MS result that confirms a peptide is the molecule you think it is.
KPV Peptide Research Overview (2026): Gut, Barrier & Mucosal Models
A research-framed overview of KPV, the alpha-MSH-derived tripeptide, focused on how it is studied in gut, mucosal-barrier, and skin models. Mechanism, the state of the preclinical evidence, and honest limits.
KPV & Anti-Inflammatory Peptide Research: Mechanisms and Limits (2026)
A research-framed overview of KPV — the alpha-MSH-derived tripeptide — and how anti-inflammatory peptides are studied in the literature. Mechanisms, the NF-kB pathway, and an honest read on the preclinical evidence.
Ipamorelin vs Hexarelin: A Research Comparison of Two GHRPs (2026)
Both are ghrelin-receptor agonists, but ipamorelin and hexarelin sit at opposite ends of the selectivity spectrum. A research-framed comparison of structure, receptor behavior, and why the two are studied so differently.
Inside a Third-Party COA Lab: How Independent Peptide Labs Actually Operate (2026)
Most coverage of third-party testing is written from the buyer's side — what to send, what to ask for. This one looks the other way: how an independent analytical lab is structured, why its independence is a business model rather than a favor, how method validation and sample intake work, and where the real limits of a third-party COA come from.
Injection-Site Reactions in Peptide Research: Causes and Documentation (2026)
A research-framed look at the most common finding in injectable peptide studies — local reactions at the administration site — covering why they happen, how formulation and technique drive them, and how studies record them. Methodology only, not usage guidance.
In-House vs Third-Party Peptide Testing: Who Tested It, and Why That Changes Everything (2026)
The same HPLC instrument can produce a result you should trust or a result you should discount — the difference is who ran it and whether they had a stake in the answer. Here is how in-house vendor testing and independent third-party testing actually differ, and when each one is enough.
IGF-1 LR3 Research Overview (2026): The Long-Acting IGF-1 Analog
A research-framed overview of IGF-1 LR3 — the long-acting insulin-like growth factor analog. Structure, why it resists binding proteins, how it relates to the GH/IGF-1 axis, and an honest read on the evidence.
HPLC vs Mass Spectrometry: Two Different Questions in Peptide Verification (2026)
HPLC and mass spectrometry are routinely lumped together as 'the lab tests,' but they answer fundamentally different questions. One measures how pure a sample is; the other measures whether it is the right molecule at all. Here is what each technique sees, what it is blind to, and why a complete result needs both.
HPLC Peak Integration: How a Purity Percentage Is Actually Calculated (2026)
A purity number on a COA is not measured directly — it is calculated from the area under the peaks on a chromatogram. This guide goes deep on the math: peak area versus peak height, area-percent normalization, why integration choices change the number, and the resolution and tailing metrics that decide whether the number is even trustworthy.
How to Read a Peptide Research Study Critically: A 7-Question Checklist (2026)
A practical, research-framed checklist for dissecting any peptide study — sample size, controls, blinding, endpoints, effect size, conflicts, and replication — so you can tell signal from noise.
How the Body Clears Peptides: Renal Filtration & Proteases (2026)
Two systems dominate peptide elimination — kidney filtration and enzymatic breakdown by proteases. A research-framed look at the clearance machinery itself, why native peptides disappear fast, and how engineered analogs evade it.
How Peptides Are Synthesized and Tested: From SPPS to HPLC and Mass Spec (2026)
A research-framed walkthrough of how research peptides are made (solid-phase peptide synthesis) and how their purity and identity are verified (HPLC and mass spectrometry) — the chemistry behind every Certificate of Analysis.
How Peptide Research Evidence Is Evaluated: A Hierarchy-of-Evidence Guide (2026)
Not all peptide evidence carries equal weight. A research-framed walk through the evidence hierarchy — from mechanism and cell work up to randomized trials — and how to weigh what you read.
Hexarelin: A Research Overview of the Potent GHRP (2026)
A research-framed overview of hexarelin — the potent hexapeptide growth-hormone secretagogue, how it differs from selective GHRPs like ipamorelin, its distinctive cardiac-receptor research strand, and what the literature does and doesn't establish.
Growth Hormone Secretagogue Mechanisms (2026): How GHRH-R and GHS-R1a Signal
A molecular-level look at how growth-hormone secretagogues actually work — the GHRH receptor's Gs/cAMP arm, the ghrelin receptor's Gq/phospholipase-C arm, somatostatin's brake, and why pulsatility and receptor desensitization shape the literature.
GMP-Grade vs Research-Grade Peptides: What the Labels Actually Mean (2026)
"GMP-grade" and "research-grade" describe two different manufacturing standards, not two purity numbers. Here is what each term actually certifies, why a research-grade vial can still test clean, and how to read the distinction without being marketed at.
GLP-1 vs GIP Receptor Biology Compared (2026): The Two Incretin Receptors
A side-by-side look at the two incretin receptors — GLP-1R and GIPR. Native ligands, tissue distribution, shared Gs/cAMP signaling, and the biology that explains why a dual co-agonist is not just a stronger single agonist. A research-framed receptor comparison.
GLP-1 Receptor Agonist Mechanism Explained (2026): Signaling Deep Dive
How GLP-1 receptor agonists work at the molecular level — receptor binding, Gs/cAMP signaling, the incretin effect, and why single, dual, and triple agonists differ. A research-framed mechanism guide covering semaglutide, tirzepatide, and retatrutide.
GLP-1 Peptide Titration Schedules Explained: Why Research Protocols Step the Dose (2026)
Why published research on GLP-1 receptor agonists like semaglutide and tirzepatide starts low and steps up — the pharmacology behind titration, framed as literature description rather than a dosing regimen.
GLP-1 and Gastric Emptying: The Gut-Motility Research Angle (2026)
Beyond insulin: how GLP-1 receptor signaling is studied in the context of gastric emptying and gut motility — vagal pathways, the brake on stomach transit, and why this arm matters for research design. Research-use framing throughout.
GHRP vs GHRH: The Two Growth-Hormone Secretagogue Classes Explained (2026)
A research-framed explanation of the two main growth-hormone secretagogue classes — GHRH analogs and GHRP/ghrelin-mimetics — including their distinct receptors, why they are often studied together, and how to read the literature accurately.
GHRP-2 vs GHRP-6 Research (2026): Two Ghrelin-Mimetics Compared in the Literature
A research-framed comparison of GHRP-2 and GHRP-6 — two peptides in the same ghrelin-mimetic class, what distinguishes them in the literature (appetite signaling, selectivity, cortisol/prolactin discussion), and how to read intra-class differences accurately.
GHK-Cu vs Collagen-Stimulating Compounds: A Research Comparison (2026)
How does the copper peptide GHK-Cu compare with the other compounds studied for collagen and extracellular-matrix support — retinoids, vitamin C, and matrix-signaling peptides? A research-framed look at distinct mechanisms.
GHK-Cu Topical vs Injectable: What the Research Routes Actually Differ On (2026)
A research-framed comparison of how GHK-Cu has been studied topically versus by injection — skin penetration, copper stability, and why the route changes what the data can tell you. Mechanism, not advice.
GHK-Cu Mechanism: How the Copper Peptide Actually Works (2026)
A research-framed deep dive into GHK-Cu's mechanism — copper coordination chemistry, copper delivery and exchange, the proposed gene-expression modulation findings, and what separates established coordination chemistry from speculative signaling claims.
The GH/IGF-1 Axis Explained for Research (2026): From Hypothalamus to IGF-1
A systems-level map of the growth hormone axis — hypothalamic GHRH and somatostatin, pituitary GH release, hepatic IGF-1, and the feedback loops that govern the whole cascade. Where GHRH analogs and GH secretagogues plug in, framed for research use only.
The FDA's 2026 Stance on Compounded and Bulk Peptides, Explained
The FDA's position on peptides lives almost entirely in the compounding and bulk-drug-substance rules — a channel separate from the research-chemical market. This is an informational breakdown of what those rules govern and what they don't. Not legal advice.
Epithalon vs MOTS-c: Two Longevity Peptides, Two Different Sciences (2026)
Both get filed under 'longevity peptides,' but Epithalon and MOTS-c come from opposite corners of cell biology — one a telomerase-hypothesis tetrapeptide, the other a mitochondrial-derived signaling peptide. A research-framed comparison.
Epithalon and Telomere Research: What the Literature Actually Shows (2026)
A careful, research-framed look at Epithalon (epitalon) and the telomere/telomerase hypothesis — what the peptide is, what the science has and hasn't established, and how to read the claims critically.
Epithalon: A Research Overview Beyond the Telomere Headlines (2026)
A broad, research-framed overview of Epithalon (epitalon) — its pineal-bioregulator origins, its place in the chronobiology and neuroendocrine literature, and what the science supports versus the marketing, looking past the telomere claim alone.
Endotoxin and Sterility Testing for Peptides: The QC Layer COAs Usually Skip (2026)
Purity tells you what fraction of a vial is the target peptide. It says nothing about bacterial contamination. Here is what endotoxin and sterility testing actually measure, why they are distinct from HPLC purity, and why most peptide COAs leave them off.
DSIP (Delta Sleep-Inducing Peptide): A Research Overview (2026)
A research-framed overview of DSIP (delta sleep-inducing peptide) — what the nonapeptide is, the sleep and neuroendocrine hypotheses around it, what the literature has and hasn't established, and how to read the claims critically.
Dose-Response Design in Peptide Research: Why One Dose Tells You Almost Nothing (2026)
A research-framed guide to dose-response design in peptide studies — why multiple dose levels beat a single dose, monotonic vs biphasic curves, and how a one-dose study hides as much as it shows.
Dihexa Research Overview (2026): Angiotensin IV Analog, HGF/c-Met & the Synaptogenesis Hypothesis
A research-framed overview of Dihexa — an orally active angiotensin IV-derived compound studied for the hepatocyte growth factor (HGF)/c-Met pathway and synaptogenesis. What is established, what is preclinical, and how to read the literature without overstating it.
The Most Common Peptide Reconstitution Errors (and How to Catch Them)
Reconstitution is short and simple, which is exactly why the errors are easy to make and hard to notice. The recurring mistakes that quietly compromise a research vial — wrong solvent, foam from shaking, the silent factor-of-two volume slip — and the checks that catch each one.
Common Peptide Side Effects Observed in Research (2026)
A research-framed catalogue of the adverse-effect categories most frequently documented in peptide studies — local, systemic, metabolic, and immunogenic — described as literature observations under controlled conditions, never as outcomes anyone should expect from use.
Collagen & Wound-Healing Peptide Research: The Matrix Story (2026)
A research-framed guide to how peptides are studied in collagen synthesis and wound healing — the phases of repair, GHK-Cu and the copper-peptide literature, and an honest read on what the evidence supports.
Cellular Senescence and Peptides: What the Research Is Really Asking (2026)
A research-framed explainer on cellular senescence — what senescent cells are, what the SASP is, and how peptide and senolytic research intersects with the biology of aging. Hedged, accurate, no hype.
Calculating Measured Amounts Across Different Vial Sizes (2026)
The same syringe reading means different amounts on a 5 mg vial than on a 10 mg one. How to hold a target amount constant when the vial size changes, why the solvent volume is the lever that keeps your syringe readings consistent, and the conversions that prevent a silent factor error when you switch vials.
Cagrilintide Research Overview (2026): The Amylin Analog Studied Alongside GLP-1 Peptides
A research-framed overview of cagrilintide — a long-acting amylin-receptor agonist studied in the metabolic literature, why it is mechanistically distinct from GLP-1 peptides, and how the amylin/GLP-1 co-investigation is framed in research.
Blood-Brain-Barrier Peptide Research: How Neuropeptides Reach the CNS (2026)
A research-framed explainer on why most peptides can't cross the blood-brain barrier, the mechanisms that let some through, and why intranasal delivery dominates CNS neuropeptide research. Research use only.
Blinding in Peptide Research Studies: Why Who-Knows-What Decides What You Can Trust (2026)
A research-framed guide to blinding in peptide studies — single, double, and triple blind, why unblinding corrupts soft endpoints, and how to spot blinding failures when reading the literature.
BDNF and Neuropeptide Research: Neuroplasticity, the TrkB Pathway & What's Established (2026)
A research-framed explainer on BDNF — what it does, how it signals through TrkB, why neuropeptides keep targeting it, and how to separate established neurobiology from speculative peptide claims. Research use only.
Batch-to-Batch Consistency in Peptide Manufacturing: Why Lots Vary and How to Verify They Don't (2026)
A single clean Certificate of Analysis tells you about one lot — not the next one. Batch-to-batch consistency is the property that determines whether a vendor's quality is reproducible or a lucky draw. Here is why peptide lots vary, and how a researcher actually verifies consistency over time.
AOD-9604 Mechanism: A Research Overview of the hGH Fragment (2026)
A mechanism-first look at AOD-9604 — what the residue 176–191 fragment of human growth hormone is studied to do, the lipolysis-without-IGF-1 rationale, the open mechanistic questions, and how it differs from secretagogues. Research-use framing only.
Animal Models in Peptide Research: What Rodent Studies Can and Can't Tell You (2026)
Most peptide evidence runs through animal models. A research-framed look at why they're used, what they capture that cell work misses, and the specific ways they fail to predict human outcomes.
Angiogenesis in Peptide Research: Why New Blood Vessels Matter (2026)
A research-framed explainer on angiogenesis — the formation of new blood vessels — and why it is a recurring theme in peptide studies on tissue repair. Mechanisms, the VEGF pathway, and the limits of the evidence.
Agonist vs Antagonist vs Partial Agonist (2026): What Actually Happens at the Receptor
Binding is only half the story — what a peptide does after it binds is what splits the pharmacology into agonists, antagonists, partial agonists, and inverse agonists. A research-framed explainer of efficacy, the ceiling effect, and why 'partial' isn't 'weak.'
No articles match that search. Try a compound name (BPC-157, semaglutide), a supplier, or a term like “COA” or “HPLC.”
Independent testing, not paid placement
Every guide in this library traces back to the same blinded HPLC evaluation — 38 samples, 8 US suppliers, zero sponsorships. ROEHN Research scored highest at 9.6/10 and was the only supplier where every tested sample met its label claim. Readers save 15% with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity